CY1124726T1 - Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv - Google Patents

Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv

Info

Publication number
CY1124726T1
CY1124726T1 CY20211100979T CY211100979T CY1124726T1 CY 1124726 T1 CY1124726 T1 CY 1124726T1 CY 20211100979 T CY20211100979 T CY 20211100979T CY 211100979 T CY211100979 T CY 211100979T CY 1124726 T1 CY1124726 T1 CY 1124726T1
Authority
CY
Cyprus
Prior art keywords
derivatives used
quinazoline derivatives
treat hiv
compounds
hiv
Prior art date
Application number
CY20211100979T
Other languages
English (en)
Inventor
Petr Jansa
Petr Simon
Eric LANSDON
Yunfeng Eric HU
Ondrej Baszczynski
Milan DEJMEK
Richard L. Mackman
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY1124726T1 publication Critical patent/CY1124726T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Στο παρόν περιγράφονται ενώσεις του τύπου (Ι) και ταυτομερή και φαρμακευτικά άλατα αυτών, συνθέσεις και σκευάσματα που περιέχουν τις εν λόγω ενώσεις, και μέθοδοι χρήσης και παρασκευής των εν λόγω ενώσεων.
CY20211100979T 2014-12-24 2021-11-10 Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv CY1124726T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096748P 2014-12-24 2014-12-24
EP15832711.4A EP3237398B1 (en) 2014-12-24 2015-12-23 Quinazoline derivatives used to treat hiv
PCT/US2015/000460 WO2016105564A1 (en) 2014-12-24 2015-12-23 Quinazoline derivatives used to treat hiv

Publications (1)

Publication Number Publication Date
CY1124726T1 true CY1124726T1 (el) 2022-07-22

Family

ID=55305044

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100979T CY1124726T1 (el) 2014-12-24 2021-11-10 Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv

Country Status (41)

Country Link
US (5) US9730936B2 (el)
EP (4) EP3237398B1 (el)
JP (2) JP6367489B2 (el)
KR (2) KR102288855B1 (el)
CN (2) CN111574464A (el)
AR (1) AR103252A1 (el)
AU (1) AU2015371198B2 (el)
BR (1) BR102015032361B1 (el)
CA (1) CA2972021C (el)
CL (1) CL2017001675A1 (el)
CO (1) CO2017006214A2 (el)
CR (1) CR20170281A (el)
CU (1) CU20170089A7 (el)
CY (1) CY1124726T1 (el)
DK (1) DK3521282T3 (el)
DO (1) DOP2017000151A (el)
EA (2) EA035746B1 (el)
EC (1) ECSP17039611A (el)
ES (3) ES2715507T3 (el)
HK (1) HK1244001B (el)
HR (1) HRP20211543T1 (el)
HU (1) HUE058296T2 (el)
IL (2) IL253059B (el)
LT (1) LT3521282T (el)
MA (1) MA48448A (el)
MD (1) MD4650B1 (el)
MX (2) MX367574B (el)
MY (1) MY189761A (el)
NZ (1) NZ733174A (el)
PE (1) PE20171306A1 (el)
PH (1) PH12017501191B1 (el)
PL (3) PL3960735T3 (el)
PT (2) PT3521282T (el)
SA (1) SA517381826B1 (el)
SG (2) SG10202101143VA (el)
SI (2) SI3521282T1 (el)
SV (1) SV2017005471A (el)
TR (1) TR201903672T4 (el)
TW (3) TWI770552B (el)
UA (1) UA117796C2 (el)
WO (1) WO2016105564A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
CA2972014C (en) 2014-12-24 2019-09-24 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of hiv
AU2015371257B2 (en) 2014-12-24 2018-09-06 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of HIV
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CR20190084A (es) 2016-08-19 2019-05-02 Gilead Sciences Inc Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN111836805B (zh) 2018-02-15 2023-07-14 吉利德科学公司 吡啶衍生物及其用于治疗hiv感染的用途
CA3175557A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
US20200347036A1 (en) 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
CN114727999A (zh) 2019-11-26 2022-07-08 吉利德科学公司 用于预防hiv的衣壳抑制剂
TW202200161A (zh) 2020-03-20 2022-01-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
CA3176531A1 (en) 2020-04-24 2021-10-28 Sumitomo Pharma Co., Ltd. 2-heteroarylaminoquinazolinone derivative
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
WO2022103758A1 (en) 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
TW202342448A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
TW202400165A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197420A (en) 1980-07-01 1984-04-27 Ici Australia Ltd -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
ATE339406T1 (de) * 1999-09-23 2006-10-15 Astrazeneca Ab Chinazoline verbindungen als heilmittel
AU1462101A (en) 1999-11-22 2001-06-04 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
WO2002024667A1 (en) 2000-09-20 2002-03-28 Merck Patent Gmbh 4-amino-quinazolines
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2004108711A1 (en) 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
SI2258376T1 (sl) 2004-07-27 2019-04-30 Gilead Sciences, Inc. Analogi fosfonata spojin inhibitorjev HIV
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101048410B (zh) 2004-10-29 2010-06-23 泰博特克药品有限公司 抑制hiv的双环嘧啶衍生物
JP2008526734A (ja) 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
US7816352B2 (en) 2005-03-10 2010-10-19 The Regents Of The University Of California Apoptosis inhibitors
EP1878727A4 (en) 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
DK1899322T3 (da) 2005-06-28 2009-12-14 Sanofi Aventis Isoquinolin-derivater som hæmmere af Rho-kinase
UA93882C2 (ru) 2005-07-26 2011-03-25 Санофи-Авентис Пиперидинил-замещенные производные изохинолона kak ингибиторы rho-киназы
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US7928120B2 (en) 2006-01-27 2011-04-19 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
AU2007275682B2 (en) 2006-07-20 2012-05-17 Amgen Inc. Substituted pyridone compounds and methods of use
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
JPWO2008050808A1 (ja) 2006-10-24 2010-02-25 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
ATE505458T1 (de) 2006-12-27 2011-04-15 Sanofi Aventis Cycloalkylaminsubstituierte isochinolon- und isochinolinonderivate
EP2102187B1 (en) 2006-12-27 2015-04-01 Sanofi Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
EP2125745B1 (en) 2006-12-27 2017-02-22 Sanofi Cycloalkylamine substituted isoquinolone derivatives
WO2008086462A2 (en) 2007-01-11 2008-07-17 Wyeth AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
WO2008122614A1 (en) 2007-04-06 2008-10-16 Novartis Ag 2, 6-naphthyridine derivatives as protein kinase modulators
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
CN101918365B (zh) 2007-11-16 2013-10-09 吉联亚科学股份有限公司 人类免疫缺陷病毒复制的抑制剂
EP2269993B1 (en) 2008-04-23 2013-02-27 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
WO2010018155A1 (de) 2008-08-15 2010-02-18 Basf Se Verfahren zur herstellung von nanoskaligen organischen feststoffpartikeln
JP5600116B2 (ja) 2008-12-09 2014-10-01 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体のモジュレーター
BRPI0924067A2 (pt) 2008-12-29 2016-01-26 Fovea Pharmaceuticals compostos de quinazolina substituída
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2011035416A1 (en) 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Hsp90 modulating compounds, compositions, methods and uses
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
US9102617B2 (en) 2010-06-25 2015-08-11 Rutgers, The State University Of New Jersey Antimicrobial agents
BR112012033689A2 (pt) 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
WO2012044090A2 (ko) 2010-09-29 2012-04-05 크리스탈지노믹스(주) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
KR20120038060A (ko) 2010-10-13 2012-04-23 롬엔드하스전자재료코리아유한회사 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
US8623889B2 (en) 2010-12-17 2014-01-07 Genentech, Inc. Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
PE20141066A1 (es) 2011-04-21 2014-09-05 Gilead Sciences Inc Compuestos de benzotiazol
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
PT3070081T (pt) 2012-04-20 2018-05-21 Gilead Sciences Inc Derivados do ácido benzotiazol-6-ilacético e sua utilização para tratar uma infeção por vih
NZ718708A (en) 2012-12-21 2018-11-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20140221378A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
EP2769723A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
AU2015371257B2 (en) 2014-12-24 2018-09-06 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of HIV
TWI770552B (zh) * 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
CA2972014C (en) 2014-12-24 2019-09-24 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of hiv

Also Published As

Publication number Publication date
SI3237398T1 (sl) 2019-04-30
CA2972021C (en) 2020-04-28
EA201791256A1 (ru) 2018-04-30
PL3237398T3 (pl) 2019-05-31
ES2900810T3 (es) 2022-03-18
DK3521282T3 (da) 2021-09-27
US9730936B2 (en) 2017-08-15
TWI770552B (zh) 2022-07-11
UA117796C2 (uk) 2018-09-25
MX367574B (es) 2019-08-27
CN111574464A (zh) 2020-08-25
US20230043136A1 (en) 2023-02-09
JP2018500358A (ja) 2018-01-11
SA517381826B1 (ar) 2021-10-21
MD20170070A2 (ro) 2017-12-31
KR20170131351A (ko) 2017-11-29
SV2017005471A (es) 2018-01-18
US20190134035A1 (en) 2019-05-09
EP3960735A1 (en) 2022-03-02
EP3960735B1 (en) 2023-09-13
US10206926B2 (en) 2019-02-19
US11304948B2 (en) 2022-04-19
BR102015032361B1 (pt) 2021-12-21
US20200360383A1 (en) 2020-11-19
JP6367489B2 (ja) 2018-08-01
ES2964395T3 (es) 2024-04-05
CA2972021A1 (en) 2016-06-30
TW202106667A (zh) 2021-02-16
CU20170089A7 (es) 2017-11-07
PH12017501191A1 (en) 2018-03-05
IL253059B (en) 2019-10-31
JP2018168181A (ja) 2018-11-01
BR102015032361A8 (pt) 2021-08-31
ES2715507T3 (es) 2019-06-04
EP4302830A3 (en) 2024-03-13
SG11201705215PA (en) 2017-07-28
LT3521282T (lt) 2021-11-25
MX2019009932A (es) 2019-10-02
TW201636328A (zh) 2016-10-16
EP3237398B1 (en) 2018-12-19
EA202091115A1 (ru) 2021-01-29
EP4302830A2 (en) 2024-01-10
PL3521282T3 (pl) 2022-01-03
SG10202101143VA (en) 2021-03-30
WO2016105564A1 (en) 2016-06-30
EP3521282B1 (en) 2021-08-25
NZ733174A (en) 2018-12-21
TW202237569A (zh) 2022-10-01
PL3960735T3 (pl) 2024-03-18
IL269635B (en) 2021-04-29
CL2017001675A1 (es) 2018-05-11
TWI699355B (zh) 2020-07-21
HUE058296T2 (hu) 2022-07-28
WO2016105564A8 (en) 2016-10-06
CR20170281A (es) 2017-11-08
EP3521282A1 (en) 2019-08-07
SI3521282T1 (sl) 2021-11-30
EA035746B1 (ru) 2020-08-05
PT3521282T (pt) 2021-11-29
IL253059A0 (en) 2017-08-31
AU2015371198A1 (en) 2017-07-13
CO2017006214A2 (es) 2017-10-20
BR102015032361A2 (pt) 2016-07-05
HRP20211543T1 (hr) 2022-01-07
IL269635A (en) 2019-11-28
PT3237398T (pt) 2019-03-06
EP3960735C0 (en) 2023-09-13
CN107278201A (zh) 2017-10-20
TR201903672T4 (tr) 2019-04-22
US10548898B2 (en) 2020-02-04
MD4650B1 (ro) 2019-09-30
KR20190133068A (ko) 2019-11-29
CN107278201B (zh) 2020-05-19
PH12017501191B1 (en) 2018-03-05
US20160250215A1 (en) 2016-09-01
MY189761A (en) 2022-03-03
AR103252A1 (es) 2017-04-26
KR102049476B1 (ko) 2019-11-28
MA48448A (fr) 2021-04-28
EP3237398A1 (en) 2017-11-01
KR102288855B1 (ko) 2021-08-11
ECSP17039611A (es) 2017-07-31
PE20171306A1 (es) 2017-09-05
US20170354656A1 (en) 2017-12-14
DOP2017000151A (es) 2017-09-15
HK1244001B (zh) 2020-01-10
MX2017008521A (es) 2018-03-01
AU2015371198B2 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
EA201591890A1 (ru) Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201692003A1 (ru) Макроциклические производные пиримидина
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
CL2018000363A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana.
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов